Genomic Biomarkers Market
Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The genomic biomarkers market is projected to reach USD 50.31 billion by 2030, up from USD 29.00 billion in 2025, at a CAGR of 11.6% from 2025 to 2030. Genomic biomarkers are measurable features of DNA and RNA used to aid disease diagnosis, characterize disease states, and guide therapeutic decision-making. This market includes the consumables, instruments, and specialized services required for genomic biomarker discovery and validation.
KEY TAKEAWAYS
-
BY REGIONThe North American genomic biomarkers market was the fastest growing segment with a CAGR of 11.8% in 2024.
-
BY OfferingsBy type, the consumables segment is expected to dominate the market, by revenue share.
-
BY TechnologyBy technology, the PCR segment dominate the genomic biomarkers market.
-
BY APPLICATIONBy application, the cancer segment is expected to dominate the market during the study period.
-
COMPETITIVE LANDSCAPEThermo Fisher Scientific, Roche, and Illumina were identified as some of the star players in the genomic biomarkers market (global), given their strong market share and product footprint.
-
COMPETITIVE LANDSCAPEMyriad Genetics, Inc., BioMérieux S.A., and GRAIL, Inc have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The genomic biomarker market is expanding rapidly, driven by the mainstreaming of precision medicine, broader reimbursement for genomics-based tests, and the accelerating adoption of NGS and advanced bioinformatics across oncology and chronic disease management
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The genomic biomarkers market is experiencing rapid growth, driven by advances in personalized and targeted therapies. The increasing use of genomic analyses in cancer diagnosis, therapy, and clinical trials is fueling demand for accurate DNA and RNA tests and sequencing. As laboratories and pharmaceutical firms adopt high-throughput, multi-disease testing, the need for standardized, validated biomarker solutions that deliver reliable, replicable results has increased. This trend has also accelerated drug development and patient selection, thereby improving patient treatment.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Growing use of genomic testing in oncology, rare diseases, and inherited disorders
-
Rapid advancements in NGS, PCR, and multi-omics technologies
Level
-
Expensive genomic testing and analysis
Level
-
Expansion of liquid biopsy and non-invasive genomic testing
Level
-
Ensuring test standardization, accuracy, and clinical validity
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing use of genomic testing in oncology, rare diseases, and inherited disorders
Increase in the number of patients undergoing genomic tests for cancer, rare diseases, and inherited disorders, prompting hospitals and labs to ramp up investment in genomics platforms and services.
Restraint: Expensive genomic testing and analysis
Despite falling sequencing costs, comprehensive genomic testing with expert data analysis remains expensive, limiting broader adoption in routine clinical practice and population screening.
Opportunity: Expansion of liquid biopsy and non-invasive genomic testing
Liquid biopsy and other non-invasive genomic tests are gaining momentum because they are less invasive for patients, allow frequent monitoring, and enable earlier detection and response assessment
Opportunity: Ensuring test standardization, accuracy, and clinical validity
Variation in lab methods, sequencing platforms, and data-interpretation pipelines makes it difficult to guarantee consistent, clinically reliable genomic results across settings
GENOMIC BIOMARKERS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
NGS panels and Oncomine assays used for genomic biomarker testing in oncology and hereditary disease, integrated with sample-to-answer workflows in hospital and reference labs. | Enables comprehensive biomarker profiling in a single run, speeds up reporting, and supports routine use of precision oncology tests |
 |
Cobas companion diagnostics and NGS solutions for tumor genomic profiling and targeted therapy selection in cancer patients. | Links genomic biomarkers directly to approved drugs, improves treatment selection, and supports broader adoption of personalized cancer care |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The genomic biomarkers market operates as a tightly interconnected ecosystem of test developers, sequencing solution providers, lab companies, pharma companies, service partners, and end users. Companies such as Illumina develop approved genomic panels, liquid biopsy tests, and analytical software solutions under stringent diagnostic regulatory requirements, while hospital and reference labs employ these for patient stratification for specific therapies and for monitoring therapy response. The pharma industry, CRO companies, and biomarker service companies integrate these tests into clinical trials and companion diagnostics, while distributors and payers work behind the scenes to ensure that these tests remain available to more patients under precision medicine.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Genomics Biomarkers Market, By Offerings
In?? 2024, Consumables had the highest share by offerings due to their recurring use in high-volume clinical and research testing
Genomics Biomarkers Market, By Type
In?? 2024, Safety biomarkers currently account for the largest share of the overall biomarkers market by type, reflecting their broad use in early-stage drug development to monitor toxicity and de-risk pipelines
Genomics Biomarkers Market, By Technology
Next-generation sequencing (NGS) remained one of the most widely used technologies for genomic biomarker testing due to its relatively low cost, fast turnaround, and suitability for targeted assays that many clinical labs can run routinely.
Genomics Biomarkers Market, By Application
Cancer dominated the genomics biomarkers market, driven by the rapid uptake of tumor profiling, minimal residual disease tests, and liquid biopsies that help match patients to targeted and immunotherapies.
Genomics Biomarkers Market, By End User
Pharmaceutical & biotechnology companies accounted for a major share of genomic biomarker testing, as these organizations rely on genomic biomarkers throughout the entire drug-development lifecycle, from target discovery and patient stratification to response monitoring and companion-diagnostic development
REGION
Asia Pacific to be fastest-growing region in market during forecast period
In 2024, the Asia Pacific region emerged as one of the fastest-growing markets for genomics biomarkers, driven by rising cancer burdens and national precision-medicine initiatives across Asia Pacific countries. Rapid expansion of NGS-enabled hospital labs, increased use of liquid biopsy and hereditary cancer testing, and strong participation by regional sites in biomarker-driven clinical trials are accelerating demand for prognostic and predictive genomic assays across both public and private healthcare systems in the Asia Pacific.
GENOMIC BIOMARKERS MARKET: COMPANY EVALUATION MATRIX
The genomic biomarkers market matrix positions Thermo Fisher Scientific as a star player, due to its broad Oncomine test menu, strong sequencing footprint, and partnerships with cancer centers and pharma companies. QIAGEN is catching up as an emerging leader, using its NGS panels, digital PCR tools, and companion-diagnostic deals to win labs seeking flexible, targeted biomarker testing options.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- THERMO FISHER SCIENTIFIC INC. (US)
- F. HOFFMANN-LA ROCHE LTD (Switzerland)
- ILLUMINA, INC. (US)
- QIAGEN (Germany/Netherlands)
- BIO-RAD LABORATORIES, INC. (US)
- AGILENT TECHNOLOGIES, INC. (US)
- EUROFINS SCIENTIFIC (Luxembourg)
- QUANTERIX (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 26.78 Billion |
| Market Forecast in 2030 (Value) | USD 50.30 Billion |
| Growth Rate | CAGR of 11.6% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
WHAT IS IN IT FOR YOU: GENOMIC BIOMARKERS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Usage insights by CDMO/clinical trial sponsors for genomic biomarker testing | Mapped how prognostic and predictive biomarkers are used across early- and late-phase oncology trials, including sample types, preferred NGS/PCR platforms, panel sizes, and turnaround-time expectations at central and local labs.? | Helps vendors target high-value trial stages with fit-for-purpose assays and services, sharpening key-account strategies with CDMOs and pharma biomarker teams. |
| Sustainability-focused genomic testing roadmap | Evaluated environmental footprint of biomarker testing workflows, comparing high-throughput NGS and PCR setups, consumables intensity, cold-chain needs, and emerging low-waste lab practices.? | Supports ESG-oriented customers with evidence-based recommendations on greener genomic testing options, enabling marketing of lower-waste, energy-efficient biomarker solutions. |
RECENT DEVELOPMENTS
- July 2024 : Thermo Fisher Scientific Inc., the global leader in scientific services, announced a collaboration with the National Cancer Institute (NCI) under the myeloMATCH precision medicine umbrella trial. Focused on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), the initiative leverages Thermo Fisher’s next-generation sequencing (NGS) technology to analyze patients’ bone marrow and blood for genetic biomarkers. This approach accelerates patient matching with clinical trials targeting specific mutations, streamlining the development of targeted therapies for these conditions.
- August 2024 : Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that the U.S. Food and Drug Administration (FDA) has approved its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test. The test also received approval for its first two companion diagnostic (CDx) indications.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global Genomic Biomarkers Market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the Genomic Biomarkers Market. The secondary sources used for this study include American Society of Clinical Oncology (ASCO), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organization (CDSCO), Center for Disease Evaluation and Research (CDER), Centers for Disease Control and Prevention (CDC), Chinese Medical Journal, Clinicaltrials.gov.in, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), Organization for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), PubMed, World Bank, World Health Organization (WHO), Corporate and Regulatory Filings, Annual Reports, Sec Filings, Investor Presentations, and Financial Statements; Business Magazines & Research Journals; Press Releases, MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global Genomic Biomarkers Market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & and biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, across six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This preliminary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Genomic Biomarkers Market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Market Definition
A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes. The Genomic Biomarkers Market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery and development, personalized medicine, and clinical research. It also studies the adoption of biomarkers across key research areas, such as oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type of biomarkers, including safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarker landscape.
Stakeholders
- Academic & Research Institutes
- Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors
- Contract Research Organizations (CROs)
- Biomarkers Service & Software Providers
- Diagnostics Companies
- Market Research and Consulting Firms
- Pharmaceutical and Biotechnology Companies
- Regulatory Agencies
- Venture Capitalists
- Forensics Labs
- Government organizations
- Private research firms
- Contract development and manufacturing organizations (CDMOs)
- Hospitals and Diagnostic Laboratories
Report Objectives
- To define, describe, and forecast the global Genomic Biomarkers Market based on offering, type, research area, technology, disease indication, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments in six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global Genomic Biomarkers Market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the Genomic Biomarkers Market
- To benchmark players in the Genomic Biomarkers Market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Genomic Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Genomic Biomarkers Market